CS

:   caesarean section

HA

:   hand assisted

Lap.

:   Laparoscopic

N/A

:   not available

PN

:   partial nephrectomy

RAPN

:   robot‐assisted partial nephrectomy

RCC

:   renal cell carcinoma

RN

:   radical nephrectomy

Keynote messageWe experienced the successful management of a patient with RCC during the antenatal period. The association between rapid tumor growth and progesterone receptor based on histopathological analysis of the tumor was suggested.

Introduction {#iju512098-sec-0005}
============

Although a diagnosis of cancer during pregnancy is rare, approximately one in every 1000 pregnant women is diagnosed with cancer during the prenatal period.[1](#iju512098-bib-0001){ref-type="ref"} Among urological tumors, RCC is the most common during pregnancy.[2](#iju512098-bib-0002){ref-type="ref"} We describe a case of RCC during pregnancy and speculate about rapid growth of the tumor, based on unique pathological findings.

Case presentation {#iju512098-sec-0006}
=================

A 39‐year‐old woman presented to the former hospital due to abnormal findings in her right kidney during an ultrasound on a physical examination. At the time, she was 18 weeks pregnant. The ultrasound findings comprised a heterogeneous, well‐demarcated mass at the middle pole of the right kidney with an approximate diameter of 28 mm (Fig. [1](#iju512098-fig-0001){ref-type="fig"}a). Magnetic resonance imaging revealed a multifocal cystic renal mass at the middle pole (Fig. [1](#iju512098-fig-0001){ref-type="fig"}b). The initial treatment plan was observation, followed by resection after birth. However, the tumor increased in size by 4 mm over a period of 4 weeks (Fig. [1](#iju512098-fig-0001){ref-type="fig"}c). Thus, the patient was recommended to undergo resection, and was referred to our hospital.

![(a) Abdominal ultrasound revealing a heterogeneous, well‐demarcated mass with an approximate diameter of 28 mm at the middle pole of the right kidney at 22 weeks of gestation. (b) Magnetic resonance imaging coronal view revealing a multifocal cystic renal mass at the middle pole. (c) Abdominal ultrasound revealing a heterogeneous, well‐demarcated mass with an approximate diameter of 32 mm at the middle pole of the right kidney at 26 weeks of gestation.](IJU5-2-265-g001){#iju512098-fig-0001}

Fine‐needle biopsy was performed to rule out benign tumors, such as mixed epithelial and stromal tumors. The pathological diagnosis was RCC. As the tumor showed definite growth, we chose to perform resection after discussion with the patient, as well as our anesthesiology and obstetrical services. At 26 weeks' gestation, right open PN was performed. We chose a retroperitoneal approach in the left lateral position with fetal monitoring because we thought it to be important to perform the procedure safely in a conventional procedure. If symptoms of premature labor were observed in association with the operation, administration of a uterine contraction inhibitor was considered. The surgery was successfully completed without any problems for the patient or fetus. Compared to typical PNs, the vessels around the kidney were well‐developed; thus, more careful manipulations were needed. The patient recovered well and was discharged on postoperative day 5. Pathological examinations showed clear cell RCC, G2 \>G3, Fuhrman grade 2 (Fig. [2](#iju512098-fig-0002){ref-type="fig"}b) with progesterone receptor expression and without estrogen receptor expression (Fig. [2](#iju512098-fig-0002){ref-type="fig"}c). The patient delivered her baby naturally without further complications at 40 weeks' gestation.

![(a) Specimen. (b) Pathological identification of the lesion as clear cell RCC. (c) Progesterone receptor immunostaining showing partial positivity (Allred score 2 + 2 = 4). Magnification: ×20.](IJU5-2-265-g002){#iju512098-fig-0002}

Discussion {#iju512098-sec-0007}
==========

To date, there have been 24 reported cases of RCC during pregnancy (Table [1](#iju512098-tbl-0001){ref-type="table"}). Generally, young people exhibit translocation RCC, but the manifestation differs in pregnant patients, such that most reports of RCC during pregnancy have been the clear cell type. In these past cases, surgeries were performed in early pregnancy and the sizes of the tumors have all been \>4 cm. In 21 of 24 cases (88%), RN was performed, with eight cases (33%) receiving laparoscopic surgery.

###### 

Details of cases in which pregnant patients were diagnosed with RCC

  Reference                 Year   Age   Laterality   Tumor size           Treatment   Pathology               Mode of delivery
  ------------------------- ------ ----- ------------ -------------------- ----------- ----------------------- ----------------------------
  O\'Connor *et al*.        2004   34    Lt.          3.5 cm               Lap.RN      N/A                     Spontaneous delivery
  Sainsbury *et al*.        2004   30    N/A          N/A                  Lap.RN      N/A                     Spontaneous delivery
  Ceglowska *et al*.        2006   N/A   Rt.          N/A                  RN          N/A                     CS at the 38^th^ week
  Van Vasten *et al*.       2006   30    Lt.          6.5 cm               Lap.RN      Clear cell type         N/A
  Casella *et al*.          2007   N/A   Lt.          N/A                  RN          N/A                     N/A
  Stroup *et al*.           2008   52    Lt.          6 cm                 Lap.RN      Clear cell type         CS at the 33^th^ week
  Simon *et al*.            2008   N/A   Rt.          N/A                  RN          N/A                     Aborted
  Van der Veldt *et al*.    2008   20    N/A          N/A                  N/A         N/A                     N/A
  Lee *et al*.              2008   39    N/A          14.5 × 12 × 17 cm    Lap.RN      Clear cell type         Spontaneous delivery
  Buda *et al*.             2008   N/A   N/A          N/A                  RN          N/A                     CS at the second trimester
  Sung Yul Park *et al*.    2008   36    Lt           3.8 cm               RAPN        Conventional type       N/A
  Fynn *et al*.             2009   33    Rt.          12 × 14 cm           RN          N/A                     CS at the 26^th^ week
  Bovio *et al*.            2009   20    N/A          5.5 × 4.5 × 3.5 cm   RN          Xp11.2 translocation    N/A
  Pearson *et al*.          2009   N/A   Rt.          N/A                  RN          N/A                     CS at the 26^th^ week
  Stojnic *et al*.          2009   22    N/A          N/A                  RN          N/A                     N/A
  Armah *et al*.            2010   26    Rt.          N/A                  RN          N/A                     CS at the 34^th^ week
  Bettez *et al*.           2011   28    N/A          9.3 cm               RN          N/A                     CS at the second trimester
  Yin *et al*.              2013   32    N/A          N/A                  Lap.RN      N/A                     Spontaneous delivery
  Katayama H *et al*.       2014   46    N/A          N/A                  RN          N/A                     CS at the 26^th^ week
  Zsolt Domjan *et al*.     2014   32    Lt.          6.1 × 4.1 cm         HALLap.RN   Chromophobe cell type   Spontaneous delivery
  Daniel Ramirez *et al*.   2016   35    Rt.          7.5 cm               RAPN        Chromophobe cell type   Spontaneous delivery
  Murat Binbay *et al*.     2016   34    Rt.          6 × 6.5 × 6.5 cm     Lap.RN      Clear cell type         CS at the 36^th^ week
  Efe C Ghanney *et al*.    2017   37    Rt.          7.1 × 11 cm          RN          Clear cell type         CS at the 30^th^ week
  Ercan *et al*.            2018   36    Rt.          12 × 9 cm            RN          N/A                     CS at the 38^th^ week
  Pesent case               2018   39    Rt.          3.5 × 3 × 3 cm       PN          Clear cell type         Spontaneous delivery
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Several considerations are needed for pregnant patients with RCC. First, radical or PN must be chosen. Second, the approach should be determined: open, laparoscopic, or robotic. Although minimally invasive approaches are becoming more standardized, it is important to assess individual conditions, such as gestational week, abdominal status, the effects of pneumoperitoneum on the fetus, and tumor status (size, position, and growth speed).

If surgery is deemed necessary during pregnancy, collaboration with obstetricians and anesthesiologists is needed. Regarding anesthesia, close attention is needed to avoid hypoxia, hypotension, and the use of nonsteroidal anti‐inflammatory drugs. Notably, extended hypoxia and hypotension can lead to fetal death. Regarding obstetrics, it is important to plan for possible emergency delivery of the fetus, depending on the outcome of surgery.[3](#iju512098-bib-0003){ref-type="ref"}

Regarding the timing of resection, it can be performed safely in the first trimester for patients who are diagnosed early. Surgeries during the second and third trimesters require additional precautions to prevent uterine contractions. Uterine manipulation and hypotension should be avoided because these negatively affect uteroplacental perfusion during this period.[3](#iju512098-bib-0003){ref-type="ref"} Buda *et al*. postponed RCC resection until 28 weeks' gestation (threshold of lung maturation).[4](#iju512098-bib-0004){ref-type="ref"} In the present case, the tumor showed particularly rapid growth; thus, we thought that surgery was needed, despite the pregnancy.

RCC in pregnant patients seems to be heterogenous; each patient demonstrates differences in tumor size, status, and growth. Appropriate treatment options should be discussed with patients. Even with a plan of observation, careful follow‐up is needed with frequent ultrasound examinations to check whether the tumor shows rapid growth.

As for the rate of growth, Chawla *et al*. reported a mean growth rate of 0.28 cm/year in a meta‐analysis of 286 renal masses at a median follow‐up of 32 months.[5](#iju512098-bib-0005){ref-type="ref"}

This case showed faster growth than this average speed. We were considered that this rapid growth was derived from tumor aggressiveness. When we planned the postnatal surgery, it could be estimated up to more than 50 mm at the end of pregnancy. However, clear cell RCC even with grade 2--3 usually is less likely to demonstrate 4 mm growth within 4 weeks. We supposed to the relationship between pregnancy and the tumor rapid enlargement.

There might be two reasons for the rapid growth of the tumor in the present case. First, the volume of circulating blood increases during pregnancy, which may influence tumor growth. Consistent with this, intraoperative findings of blood vessels revealed greater dilation than that typically observed. Second, changes in the levels of estrogen and progesterone during pregnancy could aid tumor growth. In general, estrogen and progesterone reach to a high peak during pregnancy. Though the direct relationships between the estrogen/progesterone level and RCC are controversial,[6](#iju512098-bib-0006){ref-type="ref"}, [7](#iju512098-bib-0007){ref-type="ref"}, [8](#iju512098-bib-0008){ref-type="ref"}, [9](#iju512098-bib-0009){ref-type="ref"}, [10](#iju512098-bib-0010){ref-type="ref"}, [11](#iju512098-bib-0011){ref-type="ref"} several reports support that the change of estrogen and progesterone was related to the growth of RCC.[6](#iju512098-bib-0006){ref-type="ref"}, [7](#iju512098-bib-0007){ref-type="ref"}, [8](#iju512098-bib-0008){ref-type="ref"}, [9](#iju512098-bib-0009){ref-type="ref"}, [10](#iju512098-bib-0010){ref-type="ref"} However, to our knowledge, there have been no report about the histopathologically proven finding between estrogen/progesterone receptor and RCC.

In this case, we performed histopathological evaluation of estrogen and progesterone receptor expression with the hypothesis that the interaction with hormonal change and receptor expression in the tumor would affect the tumor growth. This could have contributed to the rapid tumor growth in this case. However, further studies are needed to confirm our hypothesis.
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